Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

Opinion
Video

Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.

Video content above is prompted by the following:

Clinical Brief: Real-World Evidence Supporting Elacestrant Use

Main Discussion Topics:

  • Real-world outcomes exceeding clinical trial results (unusual finding)
  • GUARDIAN database analysis: 6.4 months median time to treatment failure
  • Komoda database: 6.8 months progression-free survival (9.4 months if fulvestrant-naive)
  • Expert clinical experience aligning with real-world data
  • Importance of appropriate patient selection for optimal outcomes

Key Points for Physicians:

  • Real-world PFS (6.4-6.8 months) exceeds EMERALD trial results (3.8 months)
  • Fulvestrant-naive patients show particularly strong outcomes (9.4 months)
  • Early adopters report better results with refined patient selection
  • Confirms benefit of using elacestrant in second-line for appropriate patients
  • Real-world data validates subgroup findings from EMERALD

The real-world evidence conclusively demonstrates that proper patient selection based on EMERALD subgroup analyses results in significantly improved clinical outcomes compared with the overall trial population.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
4 experts in this video
4 experts in this video
Photo of a man wearing a suit with a blue tie in front of a dark blue background
Photo of Hope Rugo, MD
Image of a woman with blond hair in front of a dark blue background